U.S. markets open in 6 hours 55 minutes

VectivBio Holding AG (VECT)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
7.95+0.10 (+1.27%)
At close: 03:46PM EST
7.68 -0.27 (-3.40%)
After hours: 05:33PM EST

VectivBio Holding AG

Aeschenvorstadt 36
Basel 4051
41 61 551 30 3

Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Dr. Luca Santarelli M.D.Founder, CEO & DirectorN/AN/A1969
Ms. Claudia D'Augusta Ph.D.Chief Financial OfficerN/AN/A1970
Dr. Christian Meyer M.D., Ph.D.Chief Operating OfficerN/AN/A1967
Dr. Alain Bernard Ph.D.Chief Technology OfficerN/AN/A1957
Mr. Patrick MalloySr. VP of Investor Relations & Strategic CommunicationsN/AN/AN/A
Mr. Scott ApplebaumChief Legal Officer & Corp. Sec.N/AN/A1967
Mr. Michael SteiningerSr. VP & Head of HRN/AN/AN/A
Mr. Kevin Harris M.B.A.Chief Commercial OfficerN/AN/A1971
Dr. Sarah Holland Ph.D.Chief Bus. OfficerN/AN/A1963
Dr. Omar Khwaja M.D., Ph.D.Chief Medical OfficerN/AN/A1971
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


VectivBio Holding AG, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines for treatments of severe rare conditions. It develops apraglutide, a long-acting synthetic peptide analog of glucagon-like peptide-2 that is in Phase III clinical trial for the treatment of patients with short bowel syndrome-intestinal failure (SBS-IF), as well as apraglutide is in Phase II clinical trial for SBS-IF in patients with colon-in-continuity anatomy. The company is also developing apraglutide, which is in Phase II clinical trial for patients with steroid-refractory gastrointestinal acute versus host disease (aGvHD). The company was incorporated in 2019 and is headquartered in Basel, Switzerland.

Corporate Governance

VectivBio Holding AG’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.